Celmatix is a preclinical-stage biotech company based in New York, NY, dedicated to improving women's lives through better ovarian health. With a focus on decoding ovarian function, they have amassed the largest structured dataset on ovarian health and outcomes in the world, which is driving their discovery program and powering their drug development efforts. Through partnerships with industry leaders and reproductive health centers, Celmatix is working to identify and validate targets for conditions such as endometriosis, PCOS, and ovarian senescence, as well as developing next-generation female contraceptive drugs.
With a mission to change the future of medicine, Celmatix is at the forefront of research and innovation in women's health. Their groundbreaking discoveries and collaborations aim to address the unmet needs of women suffering from poor ovarian health, providing them with effective treatments and improving their overall well-being.
Generated from the website